» Articles » PMID: 26362649

Gene Expression Meta-analysis Reveals Immune Response Convergence on the IFNγ-STAT1-IRF1 Axis and Adaptive Immune Resistance Mechanisms in Lymphoma

Overview
Journal Genome Med
Publisher Biomed Central
Specialty Genetics
Date 2015 Sep 13
PMID 26362649
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancers adapt to immune-surveillance through evasion. Immune responses against carcinoma and melanoma converge on cytotoxic effectors and IFNγ-STAT1-IRF1 signalling. Local IFN-driven immune checkpoint expression can mediate feedback inhibition and adaptive immune resistance. Whether such coupled immune polarization and adaptive resistance is generalisable to lymphoid malignancies is incompletely defined. The host response in diffuse large B-cell lymphoma (DLBCL), the commonest aggressive lymphoid malignancy, provides an empirical model.

Methods: Using ten publicly available gene expression data sets encompassing 2030 cases we explore the nature of host response in DLBCL. Starting from the "cell of origin" paradigm for DLBCL classification, we use the consistency of differential expression to define polarized patterns of immune response genes in DLBCL, and derive a linear classifier of immune response gene expression. We validate and extend the results in an approach independent of "cell of origin" classification based on gene expression correlations across all data sets.

Results: T-cell and cytotoxic gene expression with polarization along the IFNγ-STAT1-IRF1 axis provides a defining feature of the immune response in DLBCL. This response is associated with improved outcome, particularly in the germinal centre B-cell subsets of DLBCL. Analysis of gene correlations across all data sets, independent of "cell of origin" class, demonstrates a consistent association with a hierarchy of immune-regulatory gene expression that places IDO1, LAG3 and FGL2 ahead of PD1-ligands CD274 and PDCD1LG2.

Conclusion: Immune responses in DLBCL converge onto the IFNγ-STAT1-IRF1 axis and link to diverse potential mediators of adaptive immune resistance identifying future therapeutic targets.

Citing Articles

IRF5 mediates adaptive immunity via altered glutamine metabolism, mTORC1 signaling and post-transcriptional regulation following T cell receptor activation.

Brune Z, Lu A, Moss M, Brune L, Huang A, Matta B bioRxiv. 2024; .

PMID: 39253451 PMC: 11382993. DOI: 10.1101/2024.08.26.609422.


The Oncogenic Lipid Sphingosine-1-Phosphate Impedes the Phagocytosis of Tumor Cells by M1 Macrophages in Diffuse Large B Cell Lymphoma.

Perry T, Masand N, Vrzalikova K, Pugh M, Wei W, Hollows R Cancers (Basel). 2024; 16(3).

PMID: 38339325 PMC: 10854869. DOI: 10.3390/cancers16030574.


Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency.

Guevara-Hoyer K, Fuentes-Antras J, de la Fuente-Munoz E, Fernandez-Arquero M, Solano F, Perez-Segura P Front Immunol. 2022; 13:937872.

PMID: 35990641 PMC: 9390007. DOI: 10.3389/fimmu.2022.937872.


Integrative OMICS Data-Driven Procedure Using a Derivatized Meta-Analysis Approach.

Cervantes-Gracia K, Chahwan R, Husi H Front Genet. 2022; 13:828786.

PMID: 35186042 PMC: 8855827. DOI: 10.3389/fgene.2022.828786.


Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.

Yin C, Zhang J, Shen M, Gu Z, Li Y, Xue W Front Oncol. 2020; 10:1520.

PMID: 32974187 PMC: 7473157. DOI: 10.3389/fonc.2020.01520.


References
1.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

2.
Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

3.
Urbanellis P, Shyu W, Khattar R, Wang J, Zakharova A, He W . The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts. Immunology. 2014; 144(1):91-106. PMC: 4264913. DOI: 10.1111/imm.12354. View

4.
Gray K, Yates B, Seal R, Wright M, Bruford E . Genenames.org: the HGNC resources in 2015. Nucleic Acids Res. 2014; 43(Database issue):D1079-85. PMC: 4383909. DOI: 10.1093/nar/gku1071. View

5.
Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View